Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?

Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?

Background: This research was designed to investigate Algorithm Guided Treatment (AGT) and clinical traits for the prediction of antidepressant treatment outcomes in Chinese patients with major depressive disorder (MDD). Methods: This study included 581 patients who had reached treatment response an...

Full description

Bibliographic Details
Main Authors:	Yuncheng Zhu, Fang Wang, Fan Wang, Hongmei Liu, Xiaoyun Guo, Zuowei Wang, Ruoqiao He, Xiaohui Wu, Lan Cao, Zhiguo Wu, Daihui Peng, Yiru Fang
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Heliyon
Subjects:	Major depressive disorder Chinese Antidepressant agents Treatment outcome
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023081598

Similar Items

Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China
by: Zhu Y, et al.
Published: (2023-04-01)

Identifying the Subtypes of Major Depressive Disorder Based on Somatic Symptoms: A Longitudinal Study Using Latent Profile Analysis
by: Xiaohui Wu, et al.
Published: (2022-07-01)

Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder
by: Yuncheng Zhu, et al.
Published: (2022-06-01)

Addition of aerobic exercise to antidepressant drug monotherapy for major depressive disorder in adults
by: Camila Sanhueza Pastén, et al.
Published: (2022-01-01)

Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands
by: Cornelis F. Vos, et al.
Published: (2021-10-01)

A Study of Antidepressant Prescription in Major Depressive Disorders in the Out-Patient Psychiatric Department of Siriraj Hospital
by: Somporn Wipisamakul, et al.
Published: (2005-08-01)

The Impact of Residual Symptoms in Major Depression
by: Joshua A. Israel
Published: (2010-08-01)

Association of inflammation cytokines with cognitive function in first-episode major depressive disorder
by: Yan Qing Xi, et al.
Published: (2025-01-01)

The influence of general practitioner and patient sex on the treatment of major depression
by: Elisabeth Jufresa-Blanch, et al.
Published: (2023-11-01)

The pharmacological management of depression – Update 2017
by: Elzbieta Osuch, et al.
Published: (2017-03-01)

Sex-Based Variations in Hemato-Physiological Characteristics of Patients with Major Depressive Disorder: Clinical and Socioeconomic Insights
by: Basim A. Abd, et al.
Published: (2024-12-01)

Neuroinflammation and major depressive disorder: astrocytes at the crossroads
by: Melissa Puentes-Orozco, et al.
Published: (2024-11-01)

The dynamic interaction between symptoms and pharmacological treatment in patients with major depressive disorder: the role of network intervention analysis
by: Claudia Savia Guerrera, et al.
Published: (2023-11-01)

Early post‐treatment blood oxygenation level‐dependent responses to emotion processing associated with clinical response to pharmacological treatment in major depressive disorder
by: Rebecca J. Williams, et al.
Published: (2021-08-01)

The role of gender factors influencing multiple dimensions of somatic symptoms in major depressive disorder patients with suicidal ideation: insights from the Chinese NSSD study
by: Ruizhi Mao, et al.
Published: (2024-10-01)

Less basal thyrotropin levels predict antidepressant response in patients with major depression
by: R. Navinés, et al.
Published: (2022-06-01)

MRI predictors of pharmacotherapy response in major depressive disorder
by: Andrew R. Gerlach, et al.
Published: (2022-01-01)

Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
by: Haiyan Liu, et al.
Published: (2023-02-01)

Clinical distinctions in symptomatology and psychiatric comorbidities between misdiagnosed bipolar I and bipolar II disorder versus major depressive disorder
by: Zhiguo Wu, et al.
Published: (2024-05-01)

The therapeutic potential of traditional Chinese medicine in depression: focused on the modulation of neuroplasticity
by: Shimeng Lv, et al.
Published: (2024-08-01)

Pharmacological Treatments for Patients with Treatment-Resistant Depression
by: Valerie L. Ruberto, et al.
Published: (2020-06-01)

Major congenital malformations in offspring of women with chronic diseases—impact of the disease or the treatment?
by: Laila Ülkü Demir, BSc (Med), et al.
Published: (2023-02-01)

The effects of physiotherapy methods combined with respiratory and relaxation exercises on patients with major depression
by: Elisa Calisgan, et al.
Published: (2020-12-01)

Functional connectivity of the amygdala subregions and the antidepressant effects of repeated ketamine infusions in major depressive disorder
by: Haiyan Liu, et al.
Published: (2024-01-01)

Identifying Key Genes and Approved Medications Associated with Major Depressive Disorder Using Network Analysis and Systems Biology
by: Yasin Parvizi, et al.
Published: (2024-09-01)

Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder
by: Yaping Wang, et al.
Published: (2023-08-01)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
by: L. Bartova, et al.
Published: (2022-06-01)

A study to identify unrecognized bipolar disorder in patients of major depressive disorder taking antidepressants
by: Kinjal Bhupendrasinh Chauhan, et al.
Published: (2022-12-01)

Risk-to-befit ratios of consecutive antidepressants for heavy menstrual bleeding in young women with bipolar disorder or major depressive disorder
by: Chuanjun Zhuo, et al.
Published: (2022-10-01)

Functional connectivity analysis on electroencephalography signals reveals potential biomarkers for treatment response in major depression
by: Shiau-Shian Huang, et al.
Published: (2023-08-01)

Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis
by: Caroline Kamp Jørgensen, et al.
Published: (2021-08-01)

From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
by: Bangshan Liu, et al.
Published: (2017-09-01)

Striatal Functional Connectivity Alterations After Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder
by: Jing An, et al.
Published: (2019-12-01)

Clinical perspectives on the influence of drug formulation on patient tolerability and use of commonly prescribed antidepressants in major depressive disorder
by: Matthew A Fuller, et al.
Published: (2013-01-01)

Clinical Phenotypes Characterization in Pharmacogenetics Testing Trials for Major Depressive Disorder Treatment
by: A. Minelli
Published: (2022-06-01)

Cardiovascular Considerations in Antidepressant Therapy: An Evidence-Based Review
by: Habibeh Yekehtaz, et al.
Published: (2015-10-01)

Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care
by: Sicras-Mainar Antoni, et al.
Published: (2012-08-01)

Prediction of pharmacological treatment efficacy using electroencephalography-based salience network in patients with major depressive disorder
by: Kang-Min Choi, et al.
Published: (2024-10-01)

Novel Pharmacological Approaches to the Treatment of Depression
by: Elias Elias, et al.
Published: (2022-01-01)

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
by: Stefano Barlati, et al.
Published: (2023-11-01)